Cost-Effectiveness of Pembrolizumab With or Without Chemotherapy for Stage IV Non-Squamous NSCLC with High PD-L1 in Switzerland

被引：0
|
作者：
Pardo, E. [1 ]
Barbier, M. [2 ]
Panje, C. [3 ]
Gautschi, O. [4 ]
Lupatsch, J. [5 ]
机构：
[1] Canton Hosp Lucerne, Med Oncol, Internal Med, Luzern, Switzerland
[2] Univ Basel, Inst Pharmaceut Med Ecpm, Basel, Switzerland
[3] Cantonal Hosp St Gallen, Radiat Oncol, St Gallen, Switzerland
[4] Canton Hosp Lucerne, Luzern, Switzerland
[5] Univ Basel, Basel, Switzerland
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 10期
关键词：
cost-effectiveness; Pembrolizumab; NSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P08.03
引用
收藏
页码：S992 / S992
页数：1
相关论文
共 50 条
  • [11] COST-EFFECTIVENESS ANALYSIS OF PD-L1 TESTING ASSOCIATED WITH PEMBROLIZUMAB FOR FIRST-LINE TREATMENT OF ADVANCED NSCLC IN CHINA
    Wu, Y.
    Tao, L.
    Chang, L.
    Wang, F.
    Sun, S.
    Sam, H.
    VALUE IN HEALTH, 2023, 26 (06) : S114 - S114
  • [12] Cost-effectiveness of immune checkpoint inhibitors in NSCLC according to PD-L1 expression
    Aguiar, Pedro, Jr.
    Perry, Luke A.
    Lopes, Gilberto L., Jr.
    LUNG CANCER MANAGEMENT, 2016, 5 (03) : 119 - 122
  • [13] The Predictive Value of PD-L1 Expression Level in Evaluating the Cost-Effectiveness of Atezolizumab/Pembrolizumab
    Lin, Shen
    Li, Yiyuan
    Gu, Dian
    Luo, Shaohong
    Huang, Xiaoting
    Dong, Liangliang
    Xu, Xiongwei
    Lin, Peili
    Weng, Xiuhua
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [14] COST-EFFECTIVENESS OF PEMBROLIZUMAB VS. DO CETAXEL FOR TREATMENT OF PREVIOUSLY TREATED PD-L1 POSITIVE ADVANCED NSCLC PATIENTS
    Huang, M.
    Lou, Y.
    Pellissier, J.
    Burke, T.
    Liu, F. X.
    Xu, R.
    Velcheti, V.
    VALUE IN HEALTH, 2016, 19 (07) : A737 - A737
  • [15] Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States
    Huang, Min
    Lou, Yanyan
    Pellissier, James
    Burke, Thomas
    Liu, Frank Xiaoqing
    Xu, Ruifeng
    Velcheti, Vamsidhar
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (02) : 140 - 150
  • [16] Cost-effectiveness analysis of pembrolizumab monotherapy and chemotherapy in the non-small-cell lung cancer with different PD-L1 tumor proportion scores
    Zhou, Kexun
    Jiang, Chenlu
    Li, Qiu
    LUNG CANCER, 2019, 136 : 98 - 101
  • [17] Cost-effectiveness of camrelizumab plus chemotherapy vs. chemotherapy in the first-line treatment of non-squamous NSCLC: Evidence from China
    Dai, Hongbin
    Wang, Wenyue
    Fan, Xin
    Chen, Yongfa
    FRONTIERS IN MEDICINE, 2023, 10
  • [18] Benchmarking the efficacy and safety of pembrolizumab plus chemotherapy to pembrolizumab monotherapy: A consecutive analysis of NSCLC patients with high PD-L1 expression
    Takumida, H.
    Horinouchi, H.
    Masuda, K.
    Shinno, Y.
    Okuma, Y.
    Yoshida, T.
    Goto, Y.
    Yamamoto, N.
    Ohe, Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S855 - S856
  • [19] Comparative real-world analysis of pembrolizumab plus chemo vs platinum-doublet alone in metastatic non-squamous NSCLC with PD-L1 low
    Attili, I.
    Valenza, C.
    Santoro, C.
    Antonarelli, G.
    Aliaga, P. Trillo
    Del Signore, E.
    Catania, C.
    Spitaleri, G.
    Passaro, A.
    de Marinis, F.
    ANNALS OF ONCOLOGY, 2022, 33 : S51 - S51
  • [20] Cost-effectiveness of first-line pembrolizumab plus chemotherapy for metastatic squamous non-small cell lung cancer (NSCLC).
    Kim, Ashley
    Devine, Beth
    Roth, Joshua A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345